Type 2 DM as monotherapy or initial combination therapy w/ metformin when diabetes is inadequately controlled by diet & exercise alone. In combination w/ other antidiabetics including insulin when these inadequately provide glycaemic control.
Adult Monotherapy, in combination w/ metformin, thiazolidinedione, metformin & sulphonylurea or insulin (w/ or w/o metformin) 100 mg daily as 1 dose of 50 mg in the morning & evening. Dual combination w/ sulphonylurea 50 mg once daily in the morning. Initial combination therapy w/ metformin 50 mg once or bd. Max: 100 mg. Moderate or severe renal impairment or ESRD 50 mg once daily.
Discontinue use if acute pancreatitis, severe & disabling arthralgia are suspected; jaundice or other signs of liver dysfunction develops. Not an insulin substitute. Not to be used in type 1 diabetes or diabetic ketoacidosis. Not recommended in NYHA class IV. Hypoglycaemia. Perform LFTs prior to & during treatment at 3-mth intervals for the 1st yr & periodically thereafter. Routine care for diabetic patients & monitor for skin disorders. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. ESRD on haemodialysis. Not to be used in hepatic impairment & if AST or ALT increased >3 x ULN. Not to be used during pregnancy & lactation. Not recommended in childn & adolescents <18 yr.
Sign Out
